Canaccord analyst Richard Close lowered the firm’s price target on Phreesia (PHR) to $33 from $38 and keeps a Buy rating on the shares. The firm said its 3Q results included essentially in-line revenue with growth at 12.7%, but with a sizable 27.9% adj-EBITDA beat and margin hitting 24.2% and rising 550 bps tear-over-year as significant operating leverage continues. Due to the current uncertainty in Pharma budgets with potential regulatory and drug pricing changes, management may be taking a more conservative approach to guidance and there arequestions on its core revenue growth.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Phreesia Reports Strong Q3 2026 Earnings and Positive Outlook
- Closing Bell Movers: Toll Brothers slips 4% after Q4 earnings miss
- Phreesia initiated with an Overweight at Barclays
- Phreesia reports Q3 adjusted EBITDA $29.1M vs. $9.8M last year